Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Emmaus Life Sciences Q3 2026 Results: Net Loss of $4.74M, Loss Widens

Emmaus Life Sciences reported a net loss of $6.7 million for the nine months ended September 30, 2026, compared to a $5.5 million loss in the prior year period, despite a 18.5% increase in net revenues to $10.2 million. The company's financial position remains constrained with a total stockholders' deficit of $68.7 million and cash and cash equivalents of only $0.97 million as of the reporting date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.93.4
Gross profit1.53.1
Profit before tax-4.7-1.5
Net income-4.7-2.1
EPS (diluted, $ a share)$-0.07$-0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-44.0%
Gross margin80.5%
Operating margin-19.5%
Source

10-Q filed with the SEC, OTC: EMMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Emmaus Life Sciences, Inc.: key numbers

Share price
$0.0320Close, Nov 20
Market cap
$2.25M
Shares outstanding
70.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Emmaus Life Sciences, Inc.

All →
6:03 AM ET 8-K
Financial Results

Emmaus Life Sciences Financial Results

Emmaus Life Sciences reported Q3 2026 net revenues of $1.9 million, a decline from $3.4 million in the prior year period, primarily due to a 44% decrease in U.S. revenues following a licensing agreement with NeoImmuneTech. The company realized a net loss of $4.7 million for the quarter, impacted by lower direct sales of Endari and an increase in other expenses related to the fair value of conversion features.

Term
Q3 2026

“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026.”

Willis Lee, Chairman and Chief Executive Officer

“The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Midde East also adversely affected net revenues in the region,”

Willis Lee, Chairman and Chief Executive Officer

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.